203 related articles for article (PubMed ID: 31545404)
21. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267
[TBL] [Abstract][Full Text] [Related]
22. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Gårdmark T; Carringer M; Beckman E; Malmström PU;
Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
[TBL] [Abstract][Full Text] [Related]
25. Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer.
Henon C; Huillard O; Preta LH; Blanchet B; Goldwasser F; Alexandre J
Clin Genitourin Cancer; 2017 Jun; 15(3):e493-e495. PubMed ID: 28233698
[No Abstract] [Full Text] [Related]
26. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Song YS; Cho JS; Cho KS; Doo SH; Chung BH; Kim SJ; Yang WJ; Song KH; Kim CI; Hong SJ
Urol Int; 2010; 85(1):47-51. PubMed ID: 20234122
[TBL] [Abstract][Full Text] [Related]
27. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
[TBL] [Abstract][Full Text] [Related]
29. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer.
Campodonico F; Mattioli F; Manfredi V; Capponi G; Pasquini P; Martelli A; Maffezzini M
Anticancer Res; 2007; 27(2):1179-83. PubMed ID: 17465260
[TBL] [Abstract][Full Text] [Related]
31. Intravesical gemcitabine: an update of clinical results.
Hendricksen K; Witjes JA
Curr Opin Urol; 2006 Sep; 16(5):361-6. PubMed ID: 16905983
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
[TBL] [Abstract][Full Text] [Related]
33. [Elevation of CA 19.9 in urothelial bladder cancer].
Bastos Oreiro M; López Rodríguez M; Monedero Martín MC; Plasencia Rodríguez C
Med Clin (Barc); 2008 Mar; 130(8):319. PubMed ID: 18358126
[No Abstract] [Full Text] [Related]
34. Efficacy of bladder perfusion of alternating hydroxycamptothecin and gemcitabine combined with low-dose tuberculin in the treatment of non-muscle invasive bladder cancer after TURBT.
Chen L; Hu W; Li G; Guo Y; Wan Z; Yu J
J BUON; 2019; 24(4):1652-1658. PubMed ID: 31646821
[No Abstract] [Full Text] [Related]
35. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
36. Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers.
Iliou A; Panagiotakis A; Giannopoulou AF; Benaki D; Kosmopoulou M; Velentzas AD; Tsitsilonis OE; Papassideri IS; Voutsinas GE; Konstantakou EG; Gikas E; Mikros E; Stravopodis DJ
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32164285
[TBL] [Abstract][Full Text] [Related]
37. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
[TBL] [Abstract][Full Text] [Related]
38. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
39. Emerging therapeutic targets in bladder cancer.
Carneiro BA; Meeks JJ; Kuzel TM; Scaranti M; Abdulkadir SA; Giles FJ
Cancer Treat Rev; 2015 Feb; 41(2):170-8. PubMed ID: 25498841
[TBL] [Abstract][Full Text] [Related]
40. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
